Determination of cross-linking residues in a pharmaceutical polymer by liquid chromatography-high resolution full scan mass spectrometry

Talanta

Volumn 76, Issue 3, 2008, Pages 509-512

  Zhang, T ^a   Watson, D G ^a   Lu, Duo ^a   Carr, D ^b   Trager, L ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b Controlled Therapeutics ^*  (United Kingdom)

Author keywords

Cross linking residue; Fourier transform mass spectrometry; Ion suppression; Manufacturing impurities

Indexed keywords

COMPLEXATION; CROSSLINKING; DECOMPOSITION; DRUG PRODUCTS; FOURIER TRANSFORM INFRARED SPECTROSCOPY; IMPURITIES;

CROSSLINKING RESIDUES; FOURIER TRANSFORM MASS SPECTROMETRY; ION SUPPRESSIONS; MANUFACTURING IMPURITIES;

BIOPOLYMERS;

EID: 44949216494     PISSN: 00399140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.talanta.2008.03.054     Document Type: Article

References (10)

1. Karol M.H., Hauth B.A., Riley E.J., and Magreni C.M. Toxicol. Appl. Pharmcol. 58 (1981) 221
2. Erjefalt I., and Persson C.G. Clin. Exp. Allergy 22 (1992) 854
3. Rattray N.J., Botham P.A., Hext P.M., Woodcock D.R., Fielding I., Dearman R.J., and Kimber I. Toxicology 88 (1994) 15
4. Liu Y.C., Sparer M.D.J., Woskie S.R., Cullen M.R., Chung J.S., Holm C.T., and Redlich C.A. Am. J. Ind. Med. 37 (2000) 265
5. Frick M., Björkner B., Hamnerius N., and Zimerson E. Contact Dermatitis 48 (2003) 305
6. McNeill M.E., and Graham N. J. Control. Release 1 (1984) 99
7. Watson D.G., Xin L.L., Midgley J.M., and Carr D. J. Pharm. Biomed. Anal. 19 (1999) 917
8. Temesi D., Law B., and Howe N. J. Pharm. Sci. 92 (2003) 2521
9. Weaver R., and Riley R.J. Rapid Commun. Mass Spectrom. 20 (2006) 2559
10. European Medicines Agency. Guideline on the Limits of Genotoxic Impurities. June 2006.